Q-omics provides the consensus-scored ANGEL1 profile across patient tissues and cancer cell-line models. ANGEL1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ANGEL1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ANGEL1 protein abundance shows 33,444 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight BRCA, and HNSC as cancer lineages where ANGEL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANGEL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANGEL1 survival associations across molecular data types. ANGEL1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANGEL1 RNA expression–survival associations across cancer types. High ANGEL1 expression shows unfavorable associations in UCEC and BLCA, but favorable associations in BRCA, PAAD, LUAD and UCS. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BRCA as the clearest survival context for ANGEL1 RNA expression.
This table summarizes ANGEL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ANGEL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANGEL1 shows lower tumor expression in KIRC and higher tumor expression in HNSC, COAD, LIHC, BLCA and STAD. The HNSC box plot shows higher ANGEL1 RNA expression in tumor versus normal tissue (log2 FC = +1.000, t-test p < 0.001).
This table shows molecular features associated with ANGEL1 in patient tissues and cancer cell lines. In patient samples, ANGEL1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ANGEL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
